Lung cancer epigenetics: emerging biomarkers

I Balgkouranidou, T Liloglou… - Biomarkers in medicine, 2013 - Taylor & Francis
Biomarkers in medicine, 2013Taylor & Francis
Lung cancer is the leading cause of cancer-related deaths worldwide, and the 5-year
survival rate is still very poor due to the scarcity of effective tools for early detection. The
discovery of highly sensitive and specific biomarkers highlighting pathological changes
early enough to allow clinical intervention is therefore of great importance. In the last
decade, epigenetics and particularly research on DNA methylation have provided important
information towards a better understanding of lung cancer pathogenesis. Novel and …
Lung cancer is the leading cause of cancer-related deaths worldwide, and the 5-year survival rate is still very poor due to the scarcity of effective tools for early detection. The discovery of highly sensitive and specific biomarkers highlighting pathological changes early enough to allow clinical intervention is therefore of great importance. In the last decade, epigenetics and particularly research on DNA methylation have provided important information towards a better understanding of lung cancer pathogenesis. Novel and promising molecular biomarkers for diagnosis and prognosis of lung cancer are continuously emerging in this area, requiring further evaluation. This process includes extensive validation in prospective clinical trials before they can be routinely used in a clinical setting. This review summarizes the evidence on epigenetic biomarkers for lung cancer, focusing on DNA methylation.
Taylor & Francis Online
以上显示的是最相近的搜索结果。 查看全部搜索结果